Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Unresectable Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 9Drug Therapy 9Bevacizumab 9Radiotherapy 8Carboplatin 8Oxaliplatin 7Cyclophosphamide 7Surgical Procedures, Operative 6Cisplatin 6Capecitabine 6tislelizumab 5Paclitaxel 5Fluorouracil 5Docetaxel 5Control Groups 5Nivolumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3fludarabine 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × endostar protein × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡